GM Biosciences Announces Refocusing of Sanofi Collaboration
A settlement between Eli Lilly and insulin users has collapsed after a federal judge’s ruling that denied class certification for the lawsuit.
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting...
Eli Lilly`s nationwide insulin pricing settlement called off
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
The pharmaceutical industry has experienced a notable uptick in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years.
Sanofi to divest cancer biotech it bought for $1B, axe 100 staffers in California
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...
Novartis, Sanofi and PhRMA push FDA on how to better handle complex trial designs
Sanofi is parting ways with the natural killer cell company Kiadis, three and a half years after buying it for $357 million.